Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07824765) titled 'Heterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026)' on Sept. 1.

Study Type: Observational [Patient Registry]

Primary Sponsor: Zhongda Hospital

Condition: Unresectable Hepatocellular Carcinoma

Recruitment Status: Not recruiting

Date of First Enrollment: September 1, 2026

Target Sample Size: 2658

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07824765

Disclaimer: Curated by HT Syndication....